Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

NeurogesX licenses neuropathic pain treatments to Astellas; sublicensed

Executive Summary

Astellas Pharma Europe has received exclusive rights to sell pain management company NeurogesX's newly approved transdermal capsaicin patch Qutenza in the European Economic Area that includes all EU members plus Iceland, Norway, Liechtenstein, Switzerland, and some Eastern European, Middle Eastern, and African countries. NeurogesX also gave Astellas an option to co-develop its Phase I neuropathic pain candidate NGX1998 (topical liquid capsaicin) and exclusively market it in the same territories.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Transdermal
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register